The antitumor action of seminal ribonuclease and its quaternary conformations  by Cafaro, Valeria et al.
FEBS 15063 FEBS Letters 359 (1995) 31-34 
The antitumor action of seminal ribonuclease and 
its quaternary conformations 
Valeria Cafaro, Claudia De Lorenzo, Renata Piccoli, Aurora Bracale, 
Maria Rosaria Mastronicola, Alberto Di Donato, Giuseppe D'Alessio* 
Dipartimento di Chimica Organica e Biologica, Universitgl Federico H di Napoli, Via Mezzoeannone 16, 80134 Napoli, Italy 
Received 6 December 1994; revised version received 22 December 1994 
Abstract It has been previously shown that the antitumor action 
of bovine seminal rihonuclease (BS-RNase) is dependent on its 
dimeric structure. However, two distinct quaternary structures, 
each in equilibrium with the other, have been described for the 
enzyme: one in which the two subunits exchange their N-terminal 
ends, the other with no exchange. Antitumor activity assays, 
carried out on homogeneous quaternary forms of the enzyme, as 
well as on dimeric mutants of bovine pancreatic RNase A, reveal 
that another structural determinant of the antitumor activity of 
BS-RNase is the exchange of N-terminal ends between subunits. 
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1. Introduction 
Bovine seminal RNase (BS-RNase) is a uniquely dimeric 
member of the vertebrate superfamily of pancreatic-type 
RNases, with two intersubunit disulfides linking identical sub- 
units [1]. Along with several members of the superfamily, and 
RNases of other families from bacteria, fungi, and flowering 
plants, it belongs to a group of ribonucleases endowed with 
intrinsic ~ec ia l  (i.e. other than catalytic) biological actions 
(RISBASES), which include such diverse and interesting bio- 
logical actions as host defense, angiogenesis, pollen control, 
and antitumor action [2]. 
The antitumor action of BS-RNase, first discovered by 
Matousek [3], has been studied in vitro and in vivo on several 
cell lines and animal models [4,5]. Recently, a powerful an- 
timetastatic activity of the protein has been observed in mice 
inoculated with Lewis lung carcinoma cells [6]. The mechanism 
of antitumor action of BS-RNase is still under study, but it has 
been determined that the dimeric structure of the enzyme pro- 
tein is essential for its antitumor action [4]. 
However, two dimeric structures have been described for 
BS-RNase, which interconvert into each other, so that BS- 
RNase is an equilibrium mixture of two quaternary conforma- 
tions [7]. One (termed M x M), is the conformation studied by 
X-ray crystallography [8], in which the subunits exchange their 
N-terminal segments; in the other (termed M- -M) ,  no ex- 
change occurs. The ratio of M x M to M = M in native BS- 
RNase is 2:1 [7]. 
Here we report that the dimeric structure is a necessary, 
but not sufficient, determinant of the antitumor action of 
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BS-RNase, as another structural determinant has been identi- 
fied in the exchange of N-terminal ends between subunits. 
2. Materials and methods 
2.1. Proteins 
Native BS-RNase was purified as described [9]. Homogeneous prep- 
arations of M x M and M = M subforms of BS-RNase were isolated 
as previously described [7]. The content of each form was measured [7] 
by gel-filtration, after selective reduction of the intersubunit di- 
sulphides, which liberates free monomers from the M = M form with 
no exchange, whereas the form with exchange (M × M) remains 
dimeric, albeit as a non-covalent dimer. 
The PLCC-AA dimeric tetra-mutant of RNase A (A19P-Q28L- 
K31C-S32C-dimeric RNase A) was prepared as described [10]. The 
CC-AA mutant of the same protein (K31C-S32C-dimeric RNase A) 
was obtained by site-directed mutagenesis, and expressed and charac- 
terized by procedures to be published elsewhere, based on the proce- 
dures described for the preparation of recombinant BS-RNase [11] and 
of the PLCC-AA mutant of RNase A [10]. 
2.2. Antitumor assay 
Protein cytotoxicity was assayed as described [4] on SVT2 cells, a 
malignant Balb C mouse fibroblast 3T3 line transformed by SV40 
(ATCC, Richmond, VA, USA), grown in Dulbecco's modified Eagle's 
medium, supplemented with 10% FCS, 4 mM glutamine, 400 U/ml 
penicillin and 0.1 mg/ml streptomycin. Cells were seeded in 24-well 
plates (2.5 x 104/well) in the presence of the protein to be tested. At 24-h 
intervals, the percent of cell survival, with respect o control cultures 
grown in the absence of the protein, was measured in triplicate. Con- 
trols on the absence of cytotoxicity of the RNases under study on the 
parent non-transformed 3T3 cells were routinely run. They consistently 
revealed no effects of the RNases on these cells. 
3. Results and discussion 
Homogeneous preparations of the two quaternary forms of 
BS-RNase, M x M (with exchange of the terminal ends be- 
tween subunits) and M = M (with no exchange), prepared using 
an established procedure [7], were tested for antitumor activity. 
This is defined as selective cytotoxicity on malignant, trans- 
formed cells (SVT2-3T3 fibroblasts), with no effects on the 
parent line before transformation (3T3 fibroblasts). The antitu- 
mor activity was measured as the percent of cell survival after 
72 h of growth in the presence of increasing concentrations of 
protein, compared to the survival of cells plated in the absence 
of the protein. As shown in Fig. 1A, the M × M form was found 
to affect the survival of malignant cells with about the same 
potency as the native enzyme, made up of both M × M and 
M = M forms in a ratio of 2:1. The M = M form instead 
appeared much less active. 
After a series of dose-response experiments, values of ICs0, 
i.e. of the protein concentration producing an inhibition of 50% 
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Fig. 1. Survival of SVT2 fibroblasts (A) grown for 72 h in the presence 
of increasing concentrations ofBS-RNase (~), and of its M x M (e) and 
M = M (A) forms, (B) determined from growth curves obtained in the 
presence of the proteins as in A, at a concentration of 30 mg/ml. 
Survival is expressed as percent of cell survival measured in the absence 
of added proteins. 
of cell survival, were determined for the M -- M and the M x M 
forms, and found to be 19 + 3.2, and 8.7 + 0.3/.tg/ml, respec- 
tively. Under the same conditions the ICs0 for BS-RNase was 
found to be 7.8 + 0.7/.tg/ml. 
These results could indicate that the M -- M form has a lower 
antitumor activity than that of the M x M form, or of native 
BS-RNase. However, a clearer picture was obtained when the 
antitumor activities of the M = M and of M x M forms were 
determined from growth curves obtained in the presence of 
30/tg/ml of each protein. The results of these experiments, 
illustrated in Fig. 1 B, show that while the activity of M × M is 
confirmed to be similar to that of native BS-RNase, that of 
M = M increases with time until at 96 h it approaches that of 
native BS-RNase, i.e. of the equilibrium mixture of M -- M and 
M x M forms. 
In fact, it has been found [7] that isolated, homogeneous 
preparations ofmetastable M -- M and M × M forms intercon- 
vert into each other under the conditions of assay (several days 
at 37°C, pH 7), so that: (i) the homogeneous M = M form is 
increasingly converted into the M × M form; (ii) the homogene- 
ous M x M form fully equilibrates within 24 h with the M = M 
form, thus generating the equilibrium mixture typical of native 
BS-RNase. Thus, under the assay conditions, (i) the activity of 
M x M would be the same as that of BS-RNase, as its partial 
transformation i to M = M would render the resulting mixture 
undistinguishable from native BS-RNase, and (ii) the M = M 
form could have an activity even lower than that observed, or 
no activity at all, as only a continuously decreasing fraction of 
the original M = M form would be present at any time in the 
cell culture. 
However, a definite conclusion as to whether the M = M 
form has low antitumor activity, or no activity at all, could not 
be reached, given the difficulty in setting up a rapid antitumor 
assay within a time frame in which little interconversion of 
forms occurs. Therefore, an alternative approach was em- 
ployed, based on the results obtained with a mutant of pancre- 
atic RNase A, a protein which shares more than 80% of its 
primary structure with BS-RNase subunit. In this study mon- 
omeric RNase A was rendered imeric by introducing into its 
chain four residues present in the sequence of BS-RNase, and 
considered essential or important for the dimeric structure of 
the protein [8]. The residues introduced into the RNase A chain 
were a Pro, a Leu, and two Cys, at sequence positions 19, 28, 
31, and 32, respectively. The dimeric mutant of RNase A (de- 
noted PLCC-AA) also possessed a strong antitumor action [10]. 
The insertion of two Cys residues and of Leu-28 was clearly 
intended to provide the mutant with the ability to form inter- 
subunit disulfides, and a strong hydrophobic interaction at the 
subunit interface, respectively. The insertion instead of Pro at 
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Fig. 2. Kinetics of the transformation at 37°C in 0.1 M Tris-acetate, 
pH 7, of the M = M quaternary form of RNase A mutants PLCC-AA 
(e) and CC-AA (©) into the M x M form. The percent of M x M form 
was obtained at the indicated time intervals by measuring by gel-filtra- 
tion aliquots of the incubation mixture for the amount of monomer 
liberated from M -= M by selective reduction of its intersubunit disul- 
fides. 
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Fig. 3. Comparison between the antitumor activity (filled bars) and the 
content of the M × M quaternary form (empty bars), of RNase A 
mutants PLCC-AA and CC-AA, with monomeric RNase A as a nega- 
tive control. The antitumor activity was determined by incubating 
SVT2 fibroblasts for 72 h in the presence of 50,ug/ml of each protein, 
and expressed as the percent of cell death with respect o untreated 
cultures. The content of M × M form was assayed as in the legend to 
Fig. 2. Assays were carried out on freshly prepared mutants and after 
an incubation of 12 days under the conditions described in Fig. 2. 
position 19 was based on the proposed role of this residue in 
favoring the exchange of N-terminal ends in BS-RNase [12]. 
Thus a mutant of RNase A, in which a Pro residue was not 
present at position 19, could be dimeric without, or with lim- 
ited, N-terminal exchange. This mutant, denoted CC-AA, in 
which only the two substitutions of Cys at sequence positions 
31 and 32 were introduced (the insertion of a Leu at position 
28 was also eliminated for the sake of simplification), was 
cloned and expressed in Escherichia coli. After extraction from 
inclusion bodies, purification and refolding, the mutant 
CCAA,  like both PLCC-AA [10] and recombinant BS-RNase 
obtained in the same expression system [11], was found to be 
a mixture of dimeric forms, made up mainly of the M = M-type 
of dimers, with a low fraction of M x M-type dimers. 
Upon incubation at 37°C in 0.1 M Tris-acetate, pH 7 [7] (see 
Fig. 2), the M = M form of PLCC-AA partially converted into 
the M x M form, until an equilibrium ratio of 2:1 between 
M x M and M = M was established, the same ratio found be- 
tween the M x M and M = M forms of BS-RNase. In the case 
of the CC-AA mutant, however, the equilibrium ratio between 
the two forms was of about 1:9. This indicated that in the 
CC-AA mutant the extent of exchange, although not absent, 
was very limited, and suggested that Pro-19, as proposed [12], 
plays an important role in determining the exchange of 
N-terminal ends in BS-RNase. 
Fig. 3 shows the results of antitumor assays carried out on 
mutants PLCC-AA and CC-AA, before and after the establish- 
ment of equilibrium between the two quaternary forms M = M 
and M x M for each mutant. Native monomeric RNase A was 
used as a negative control. In the case of PLCC-AA, in which 
equilibration between the two forms consisted in a significant 
increase in the M x M fraction, this resulted in a significant 
increase in antitumor activity; in the case of the CC-AA mu- 
tant, however, the increase in M × M form content was moder- 
ate, and no increase in antitumor activity was registered. Thus 
in mutant RNases with different degrees of N-terminal ex- 
change the extent of exchange correlates unequivocally with the 
level of antitumor activity. 
These results, and those described above, obtained with iso- 
lated BS-RNase forms M × M and M = M, suggest hat the 
apparent antitumor activity of the M = M form from natural 
and mutant dimeric RNases can be ascribed to its metastability, 
i.e. to its transformation i to the M x M lbrm occurring during 
the lengthy bioassay. On the other hand, the activity of the 
M × M form could actually be higher than that measured with 
the available bioassay. Hence the exchange of subunit N-termi- 
nal ends is another important structural feature, besides the 
dimeric structure, in determining the antitumor action of BS- 
RNase. However, the possibility that a limited, small antitumor 
activity is also present in the M = M forms of dimeric RNases 
can not be totally excluded at present. A definite, conclusive 
answer could be obtained from the construction of a mutant 
of BS-RNase, or of a dimeric mutant of RNase A, in which no 
exchange of parts between subunits takes place at all. The 
results presented here favor the prediction that such a mutant 
would be totally devoid of antitumor action. 
What is the mechanistic meaning of these observations i not 
clear. It has been proposed [13] that a higher antitumor activity 
of the M x M form of BS-RNase may be due to a higher affinity 
of this form for cellular binding sites. Another possibility is that 
the two forms of BS-RNase may be driven along different 
intracellular paths. It is known that RNase A, the tertiary 
structure of which is extremely similar to that of BS-RNase 
monomer in the M = M form [8], can be endocytosized by 
tumor cells without any adverse effects on the cells, and is 
directed toward the lysosomal district [14]. Possibly this path- 
way is accessible to M = M, which would be monomerized by 
the reducing potential of the cytosol, but not accessible to 
M × M, even after reduction of the intersubunit disulfides, as 
its dimeric structure would be maintained by non-covalent in- 
teractions [7]. It may also be considered that monomeric, disso- 
ciated BS-RNase is sensitive to the cytosolic RNase inhibitor, 
whereas dimeric BS-RNase is resistant [15]. Thus it is possible 
that the intracellular level of inhibitor is sufficient o sequester 
and inactivate the enzyme monomers as dissociated from 
M = M by the cytosolic redox potential. 
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